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he Prognostic
mpact of Septal
yectomy in Obstructive
ypertrophic Cardiomyopathy*
ugh Watkins, MD, PHD,†
illiam J. McKenna, MD, DSC, FACC‡
xford and London, United Kingdom
long-standing problem facing clinicians caring for
atients with hypertrophic cardiomyopathy (HCM) is
he scarcity of robust clinical evidence on which to base
herapeutic decisions. For most interventions, there are
o randomized controlled trial data. Rather, much of the
iterature consists of retrospective observational studies
ith historical controls. Individual referral centers with
pecialist interest have tended to develop their particular
pproaches to patient management and, even when more
han one option is available for consideration, have
ended to focus on a single choice. Once local experience
onvinces investigators that a particular treatment is
arranted (albeit by way of comparison with historical
ontrols), the opportunity to perform randomized studies
as effectively been missed.
See page 470
In this setting, the particular problem that arises is that
CM is an unusually heterogeneous condition (1). The
ifferent underlying disease genes are associated with
uantitative, and occasionally qualitative, differences in
linical features and natural history (2– 4). Therefore,
ifferent selection biases arising from methods of patient
scertainment undoubtedly influence both the genetic
akeup of a study population and the subsequent disease
utcome. A clinical practice based on families referred
fter a sudden cardiac death will yield a quite different
atient cohort from a referral practice of individuals
elected for interventional procedures for outflow ob-
truction, and both will differ from patient populations
scertained through an echocardiography service. Unsur-
risingly, conflicting findings on treatment outcomes
nsue. Early enthusiasm for novel forms of treatment has
ot always been borne out, perhaps reflecting aspects of
atient selection that were later negated by better con-
rolled data. For example, the one instance in which
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the †Department of Cardiovascular Medicine, University of Oxford, Oxford,
nd ‡The Heart Hospital, University College London, London, United Kingdom.ractice has been informed by randomized trials was the
emonstration that the apparent benefits of dual-
hamber pacing in HCM were actually very modest and
robably restricted to a small subset of patients (5).
EPTAL REDUCTION FOR SYMPTOM CONTROL
gainst this background of uncertainty, one area in which
here have been clear data and a firm consensus is that
atients with obstructive HCM who have persistent symp-
oms, or exercise limitation, despite maximum medical
herapy benefit symptomatically from procedures to reduce
he outflow gradient (6). In approximately 25% of patients
ith HCM, there is a dynamic obstruction of the left
entricular outflow tract caused by septal hypertrophy and
ystolic anterior motion of the mitral valve. In patients in
hom such an outflow gradient can be demonstrated at rest,
uch more marked gradients are provoked during exercise.
urgical septal myectomy effectively abolishes systolic ante-
ior motion of the mitral valve and the concomitant mitral
egurgitation, improving left ventricular hemodynamics
particularly the key parameter of wall stress). Long-term
xperience from a number of centers convincingly shows
hat this approach is a proven one that provides lasting
melioration of symptoms (7). Moreover, surgical mortality
n specialist centers is now 1% to 2%. Despite this, the
ptake of surgical myectomy is relatively low, with 5% of
atients with HCM being treated in this way in most case
eries. In contrast, there has been a marked proliferation of
ercutaneous, catheter-based, alcohol septal ablation, which
chieves remodeling in the left ventricular outflow tract by
ausing a localized myocardial infarction in the proximal
eptum (8–10). Although significant controversy exists
ypically because individual centers strongly favor one or
ther technique and few offer significant experience of both,
he general consensus is that operative risks, hemodynamic
enefits, and initial symptomatic benefits are broadly com-
arable (in centers with appropriate expertise) with either
echnique. A critical difference is that long-term follow-up
ata are not yet available for alcohol septal ablation, and
here are concerns that the intramyocardial scar may provide
long-term arrhythmogenic substrate and that the extent of
yocardial damage may exceed the target area and lead to
urther, undesirable, remodeling. Furthermore, pacemaker
mplantation rates are still significantly higher with the
ercutaneous procedure (5% to 10%). While these long-
erm data are awaited, there is a valid concern that the
hreshold for intervention (now that it can be performed
ercutaneously) is becoming inappropriately low. There are
o data to support use of alcohol septal ablation as “first-
ine” treatment, i.e., before trying maximum medical ther-
py, or in patients with obstruction but only minor symp-
oms; nevertheless, there may already be a trend toward
hese practices (11). In addition, the proliferation of alcohol
eptal ablation may lead to provision by low-volume oper-
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Editorial Comment August 2, 2005:477–9tors without appropriate specialist expertise in HCM
anagement and patient selection.
ROGNOSTIC IMPLICATIONS
F DYNAMIC OUTFLOW OBSTRUCTION
ecent findings regarding the natural history of patients
ith obstruction and the impact of surgical reduction on
ong-term death rates now polarize this debate further. The
ew findings potentially broaden the value of gradient
eduction, which could have major clinical implications,
mphasizing the importance of getting the facts right. Once
gain, the data only relate to surgical intervention. Early
linical studies had indicated that the presence of obstruc-
ion was not a clear, or clinically useful, predictor of the
ubsequent risk of sudden cardiac death. However, a recent
arge observational study (combining consecutive patients
rom three centers) suggested that outflow obstruction (30
m Hg at rest) was associated with a significantly greater
isk of progressive heart failure, stroke, and overall disease-
elated death (12). Although this is a single study, and the
ffect size was not large, these observations could be
nterpreted to mandate a more aggressive approach to
radient reduction, at least in patients with refractory
ymptoms. The key question, of course, is whether proce-
ures to reduce the outflow obstruction can be shown to
mprove prognosis. No randomized data exist with which to
nswer this question, but the report by Ommen et al. (13) in
his issue of the Journal could be interpreted as evidence that
urgical relief of obstruction improves long-term survival in
dults.
AN ANY ADVERSE
ROGNOSIS BE REVERSED BY MYECTOMY?
mmen et al. (13) report an observational study of 1,337
onsecutive patients with HCM drawn from four U.S. and
uropean specialist centers between 1983 and 2001. These
atients were retrospectively grouped into three categories:
atients with surgically treated outflow tract obstruction,
atients with medically treated outflow tract obstruction,
nd patients without obstruction. Survival after myectomy
as not different from survival in the nonobstructive group
ut was better than survival in the nonoperated obstructive
roup (for all-cause mortality, HCM-related mortality, and
udden cardiac death). The authors concluded that surgical
yectomy appears to improve survival in patients with
ighly symptomatic obstructive HCM. Unfortunately, all of
he surgical subjects came from one of the centers (Mayo
linic) whereas the two nonsurgical groups were drawn
rom the three other centers (patients from these centers
ho were referred for surgery were not included). Thus, as
sual in this field, concern exists regarding the biases
nherent in comparing retrospective cohorts selected for
ifferent treatments. Referrals to the Mayo Clinic for
yectomy will likely be selected for severity of symptoms in itherwise well, low-risk, patients, both in regard to HCM
nd general morbidity/mortality risk. Patients with equiva-
ent gradients who do not get referred for surgery may be
hose with adverse factors that will generate a worse prog-
osis independent of procedure, which may be particularly
he case for those described as having outflow tract obstruc-
ion with “severe functional limitation” who yet do not get
eferred. Some clues as to possible biases are apparent in the
onoperated obstructive group (older age, more atrial fibril-
ation, a greater proportion receiving amiodarone). Reason-
ble efforts have been made to measure and compare known
onfounders, and a “confirmatory analysis” focusing on
atients 45 years of age is helpful, but unknown biases
ay remain. Of note, the comparison group of 228 patients
ith outflow obstruction who did not undergo surgery (and
ho showed the adverse prognosis) are the same patients
hat generated the initial adverse natural history data (12). If
hat group is somehow not representative, then the survival
enefit ascribed to myectomy will have been exaggerated.
Survival analyses of this type also can be sensitive to
ecisions made in the statistical analysis. For example,
ppropriate discharges from an implantable cardioverter-
efibrillator have been regarded as a sudden death (eight
atients), where in fact many discharges are likely to be for
onfatal arrhythmias. Survival was censored for cardiac
ransplantation (nine patients) where, more conventionally
12), these would be considered as equivalent to deaths from
eart failure. Patients who underwent surgical myectomy in
ssociation with other procedures (mitral valve surgery,
oronary artery grafting; n  64) were excluded from the
nalysis of myectomy outcome. This group will have con-
ained high-risk patients with comorbidity, whereas such
atients will not have been excluded from the medically
anaged obstruction group. Well-known problems also
xist in comparing survival in surgical cohorts (in which
ortality between diagnosis and operation is invisible) with
edically managed cohorts followed from diagnosis in the
ame center. Reassuringly, the authors have (where possible)
erformed confirmatory analyses that suggest that their key
ndings are robust to these study design limitations.
O WHAT EXTENT SHOULD
HESE DATA ALTER PRACTICE?
or patients with refractory symptoms due to obstructive
CM, surgery can already be justified on symptomatic
rounds; an added survival advantage increases the benefit
ut does not, in fact, change the existing indication.
pecifically, it is not sound to extrapolate from these
ndings to conclude that prognosis would be improved by
yectomy in asymptomatic obstructive HCM. Neverthe-
ess, that is a plausible hypothesis that now needs proper
esting (much of the apparent late benefit in the current
eries arose from a reduction in progressive left ventricular
ysfunction, and this could plausibly be of prognostic value
ndependent of symptoms earlier in life). Equally, it is not
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August 2, 2005:477–9 Editorial Commentound to conclude that alcohol septal ablation will improve
urvival even in patients with refractory symptoms; this also
eeds formal evaluation. Thus, the relatively low uptake of
urgical myectomy seems increasingly inappropriate, and
trong arguments can be made for greater provision in
pecialist centers.
HE NEXT STEP
lthough some uncertainty remains regarding the extent of
urvival benefit afforded by myectomy, this will never be
esolved by a randomized study. Instead, because patients
ith refractory symptoms and obstruction will tend to be
eferred for an intervention anyway, the question to focus on
s which of the two current approaches confers the greater
asting benefit. With the realization that gradient reduction
ay improve survival in patients with refractory symptoms,
urely it is now time for a randomized controlled trial
etween surgical and percutaneous approaches.
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